New pill targets KRAS cancers in early human trial
Disease control
Recruiting now
This early-phase trial tests an oral drug called ALTA3263 in about 448 adults with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a KRAS mutation. The main goals are to check safety, find the right dose, and see how the body processes the drug. Part…
Phase: PHASE1 • Sponsor: Alterome Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC